360° SearchNetwork Hot Spots Trends Time Series

Publication: The Cross-Border Biotech Blog

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Friday Science Review: May 17, 2013

Parkinson’s disease, a neurodegenerative disease characterized by motor and cognitive deficits, may be caused by mutations in the Parkin gene. The Parkin gene transcribes the Parkin protein, an enzyme which has been implicated in cellular processes ... [Published The Cross-Border Biotech Blog - May 17 2013]

Entities: Protein, mutations, Parkinson's Disease

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Monday Deal Review: May 13, 2013

Welcome to your Monday Biotech Deal Review for May 13, 2013! This week saw MethylGene make waves with its announcement that it will move its business to the State of Delaware, and will be held by specially made Mirati Therepeutics. Mirati will then ... [Published The Cross-Border Biotech Blog - May 13 2013]

Entities: MethylGene Inc, CEAPRO Inc, Selling Group, Common Shares

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Friday Science Review: May 10, 2013

Stroke is the leading cause of disability in North America, but no good treatment exists for stroke beyond a few hours of its occurrence. The damaging effects of stroke occur because nerve cells in the brain require oxygen to survive; once blood-flow ... [Published The Cross-Border Biotech Blog - May 10 2013]

Entities: Neuron, Peptide, Nucleus, Oxygen

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Valuation and other biotech mysteries – Part 26: Some Final Thoughts

[Ed. This is the twenty-fourth part in Wayne's series. You can access the whole thing by clicking here . As with all commentary on this blog, these comments do not consider the investment objectives, financial situation or particular needs of any ... [Published The Cross-Border Biotech Blog - May 08 2013]

Entities: Biotechnology, Drugs, Tagamet, Capital Markets

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Friday Science Review: May 3, 2013

The use of oncolytic viruses is becoming an increasingly attractive avenue for the treatment of cancer, because these viruses are able to destroy tumor cells and also generate immune-responses directed at those same tumor cells. Using human viruses for ... [Published The Cross-Border Biotech Blog - May 03 2013]

Entities: Tumor, Virus, Stem Cell

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Valuation and other biotech mysteries – Part 25: Undervalued compared to its peers?

Entities: Biotechnology, Phase III, ConjuChem

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Monday Deal Review: April 29, 2013

Welcome to your Monday Biotech Deal Review for April 29, 2013! This week saw Ergoresearch and Amorfix close their previously announced private offerings. Trimel, meanwhile, has raised $40 million from their public offering of 50,000,000 common shares. ... [Published The Cross-Border Biotech Blog - Apr 29 2013]

Entities: Cardiome Pharma Corp, Amorfix Life Sciences Ltd, Neovasc Inc, Ergoresearch Ltd

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Friday Science Review: April 26, 2013

Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, are autoimmune disorders in which persistent bowel inflammation leads to physical damage of the intestinal tract. Research out of the Inflammation Research Network at ... [Published The Cross-Border Biotech Blog - Apr 26 2013]

Entities: Receptor, Inflammatory Bowel Disease, Inflammation

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Valuation and other biotech mysteries – Part 24: Event-Based Trading

[Ed. This is the twenty-fourth part in Wayne's series. You can access the whole thing by clicking here . Please leave comments or questions on the blog and Wayne will address them in future posts in this series. As with all commentary on this blog, ... [Published The Cross-Border Biotech Blog - Apr 25 2013]

Entities: Clinical trials, Share Price, Biotechnology, Long Position, Price Momentum

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Monday Deal Review: April 22, 2013

Welcome to your Monday Biotech Deal Review for April 22, 2013! Aeterna Zentaris has had a busy two weeks on the commercial front, signing agreements with Merck and Ergomed. However, there was a lot more action as well. Hit the break to catch up on ... [Published The Cross-Border Biotech Blog - Apr 22 2013]

Entities: Actavis, Toronto stock exchange, Merck KGaA, Common Shares, AEterna Zentaris Inc

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Friday Science Review: April 19, 2013

Author’s note: I will be taking over writing duties from John Holyoake for the Friday Science Review. If you wish to know more about me, you can find my short bio on our contributors page – http://crossborderbiotech.ca/about/ Anxiety disorders are becoming ... [Published The Cross-Border Biotech Blog - Apr 19 2013]

Entities: Autonomic Nervous System, Anxiety, Autism Spectrum, PLoS ONE, Nervous System

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Positive Share Price Performance in Q1 2013 for the Canadian Healthcare Sector (Part 2)

In this blog, I will focus on the Canadian public healthcare companies with share prices on December 31, 2012 between $0.10 and $0.99 (53 companies). Advancers outnumbered decliners by 28 to 25Average and median share price changes were 11% and 0%, ... [Published The Cross-Border Biotech Blog - Apr 17 2013]

Entities: Share Price, ProMetic Life Sciences Inc, Health Care

More Content

sort by: Date \| Relevance
Friday Science Review: May 17, 2013 [Published The Cross-Border Biotech Blog - May 17 2013]
Monday Deal Review: May 13, 2013 [Published The Cross-Border Biotech Blog - May 13 2013]
Friday Science Review: May 10, 2013 [Published The Cross-Border Biotech Blog - May 10 2013]
Valuation and other biotech mysteries – Part 26... [Published The Cross-Border Biotech Blog - May 08 2013]
Friday Science Review: May 3, 2013 [Published The Cross-Border Biotech Blog - May 03 2013]
Valuation and other biotech mysteries – Part 25... [Published The Cross-Border Biotech Blog - May 01 2013]
Monday Deal Review: April 29, 2013 [Published The Cross-Border Biotech Blog - Apr 29 2013]
Friday Science Review: April 26, 2013 [Published The Cross-Border Biotech Blog - Apr 26 2013]
Valuation and other biotech mysteries – Part 24... [Published The Cross-Border Biotech Blog - Apr 25 2013]
Monday Deal Review: April 22, 2013 [Published The Cross-Border Biotech Blog - Apr 22 2013]
Friday Science Review: April 19, 2013 [Published The Cross-Border Biotech Blog - Apr 19 2013]
Positive Share Price Performance in Q1 2013 for... [Published The Cross-Border Biotech Blog - Apr 17 2013]
Positive Share Price Performance in Q1 2013 for... [Published The Cross-Border Biotech Blog - Apr 11 2013]
Monday Deal Review: April 8, 2013 [Published The Cross-Border Biotech Blog - Apr 08 2013]
Monday Deal Review: March 25, 2013 [Published The Cross-Border Biotech Blog - Mar 25 2013]
Monday Deal Review: March 18, 2013 [Published The Cross-Border Biotech Blog - Mar 18 2013]
Monday Deal Review: March 11, 2013 [Published The Cross-Border Biotech Blog - Mar 11 2013]
Monday Deal Review: March 4, 2013 [Published The Cross-Border Biotech Blog - Mar 04 2013]
Monday Deal Review: February 25, 2013 [Published The Cross-Border Biotech Blog - Feb 25 2013]
2012 Canadian Healthcare Financings – strong bu... [Published The Cross-Border Biotech Blog - Feb 22 2013]
2012 Canadian Healthcare Share Price Performanc... [Published The Cross-Border Biotech Blog - Feb 21 2013]
Monday Deal Review: February 18, 2013 [Published The Cross-Border Biotech Blog - Feb 18 2013]
Friday Science Review: February 15, 2013 [Published The Cross-Border Biotech Blog - Feb 15 2013]
Monday Deal Review: February 11, 2013 [Published The Cross-Border Biotech Blog - Feb 11 2013]
Monday Deal Review: February 4, 2013 [Published The Cross-Border Biotech Blog - Feb 04 2013]
Monday Deal Review: January 28, 2013 [Published The Cross-Border Biotech Blog - Jan 28 2013]
Monday Deal Review: January 21, 2013 [Published The Cross-Border Biotech Blog - Jan 21 2013]
Monday Deal Review: January 14, 2013 [Published The Cross-Border Biotech Blog - Jan 14 2013]
Friday Science Review: January 8, 2013 [Published The Cross-Border Biotech Blog - Jan 11 2013]
Monday Deal Review: January 7, 2013 [Published The Cross-Border Biotech Blog - Jan 07 2013]

Blogs

sort by: Date \| Relevance
Friday Science Review: May 17, 2013 [Published The Cross-Border Biotech Blog - May 17 2013] Parkinson’s disease, a neurodegenerative disease characterized by motor and cognitive deficits, may be caused by mutations in the Parkin gene. The Parkin gene transcribes the Parkin protein, an enzyme which has been implicated in cellular processes ...
Monday Deal Review: May 13, 2013 [Published The Cross-Border Biotech Blog - May 13 2013] Welcome to your Monday Biotech Deal Review for May 13, 2013! This week saw MethylGene make waves with its announcement that it will move its business to the State of Delaware, and will be held by specially made Mirati Therepeutics. Mirati will then ...
Friday Science Review: May 10, 2013 [Published The Cross-Border Biotech Blog - May 10 2013] Stroke is the leading cause of disability in North America, but no good treatment exists for stroke beyond a few hours of its occurrence. The damaging effects of stroke occur because nerve cells in the brain require oxygen to survive; once blood-flow ...
Valuation and other biotech mysteries – Part 26... [Published The Cross-Border Biotech Blog - May 08 2013] [Ed. This is the twenty-fourth part in Wayne's series. You can access the whole thing by clicking here . As with all commentary on this blog, these comments do not consider the investment objectives, financial situation or particular needs of any ...
Friday Science Review: May 3, 2013 [Published The Cross-Border Biotech Blog - May 03 2013] The use of oncolytic viruses is becoming an increasingly attractive avenue for the treatment of cancer, because these viruses are able to destroy tumor cells and also generate immune-responses directed at those same tumor cells. Using human viruses for ...